SGIOF - ViiV Healthcare inks licensing deal with Shionogi to develop HIV integrase inhibitor

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (NYSE:GSK), with Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY) as shareholders, announces an exclusive collaboration and license agreement with Shionogi & Co. for S-365598, a third-generation investigational integrase strand transfer inhibitor (INSTI) with potential for use in ultra long-acting HIV regimens. Under the terms of the agreement, ViiV will make an upfront payment of £20M to Shionogi, a £15M payment for the achievement of a clinical development milestone and royalties on net sales. Shionogi will contribute to development costs up to an annual maximum. Preclinical studies are underway. ViiV and Shionogi intend to initiate first time in human studies with S-365598 by 2023. Recently, FDA granted Priority Review to Viiv Healthcare’s cabotegravir long-acting NDA in HIV prevention.

For further details see:

ViiV Healthcare inks licensing deal with Shionogi to develop HIV integrase inhibitor